These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 19789418)

  • 1. Lack of clinical benefit of improved angiographic results with sirolimus-eluting stents compared with paclitaxel and zotarolimus-eluting stents in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
    Choi CU; Rha SW; Chen KY; Li YJ; Poddar KL; Jin Z; Minami Y; Suh SY; Na JO; Lim HE; Kim JW; Kim EJ; Park CG; Seo HS; Oh DJ
    Circ J; 2009 Dec; 73(12):2229-35. PubMed ID: 19789418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and angiographic outcomes of drug-eluting stents in patients with large vessel and single coronary artery lesion.
    Kim U; Kim DK; Seol SH; Yang TH; Kim DK; Kim DI; Kim DS; Lee SH; Hong GR; Park JS; Shin DG; Kim YJ; Cho YK; Kim HS; Nam CW; Hur SH; Kim KB
    Clin Cardiol; 2010 Jun; 33(6):340-4. PubMed ID: 20556803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
    Kirtane AJ; Patel R; O'Shaughnessy C; Overlie P; McLaurin B; Solomon S; Mauri L; Fitzgerald P; Popma JJ; Kandzari DE; Leon MB
    JACC Cardiovasc Interv; 2009 Oct; 2(10):967-76. PubMed ID: 19850257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
    JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry.
    Novack V; Cutlip D; Kleiman N; Pencina M; Mauri L; Yen CH; Berger P; Goldberg S; Kellett M; Waksman R; Hong M; Raizner AE; Cohen DJ
    JACC Cardiovasc Interv; 2009 Aug; 2(8):767-75. PubMed ID: 19695546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of zotarolimus-eluting stents versus sirolimus-eluting stents versus paclitaxel-eluting stents for primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: results from the Korean Multicentre Endeavor (KOMER) acute myocardial infarction (AMI) trial.
    Kang WC; Ahn T; Lee K; Han SH; Shin EK; Jeong MH; Yoon JH; Park JS; Bae JH; Hur SH; Rha SW; Oh SK; Kim DI; Jang Y; Choi JW; Kim BO
    EuroIntervention; 2011 Dec; 7(8):936-43. PubMed ID: 21959255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
    Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential long-term outcomes of zotarolimus-eluting stents compared with sirolimus-eluting and paclitaxel-eluting stents in diabetic and nondiabetic patients: two-year subgroup analysis of the ZEST randomized trial.
    Jang SJ; Park DW; Kim WJ; Kim YH; Yun SC; Kang SJ; Lee SW; Lee CW; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2013 Jun; 81(7):1106-14. PubMed ID: 22899589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sirolimus- versus paclitaxel-eluting stents for the treatment of cardiac allograft vasculopathy.
    Lee MS; Tarantini G; Xhaxho J; Yang T; Ehdaie A; Bhatia R; Favaretto E; Tobis J
    JACC Cardiovasc Interv; 2010 Apr; 3(4):378-82. PubMed ID: 20398863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zotarolimus-eluting stent versus sirolimus-eluting and paclitaxel-eluting stents for percutaneous coronary intervention: a meta-analysis of randomized trials.
    Sethi A; Bahekar A; Bhuriya R; Bajaj A; Singh PP; Arora R; Khosla S
    Arch Cardiovasc Dis; 2012 Nov; 105(11):544-56. PubMed ID: 23177483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of stent length on restenosis in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: analysis based on data from the Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON).
    Rozenman Y; Witzling V; Tamari I; Turkisher V; Kriviski M; Bode C; Henry P; Teiger E; Cebrian A; Stoll HP; Spaulding C
    EuroIntervention; 2009 Jun; 5(2):219-23. PubMed ID: 19527979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial.
    Xu B; Yang Y; Yuan Z; Du Z; Wong SC; Généreux P; Lu S;
    JACC Cardiovasc Interv; 2013 Jul; 6(7):664-70. PubMed ID: 23523240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mid-term angiographic benefit of sirolimus-eluting stents compared with paclitaxel-eluting stents in patients with acute myocardial infarction.
    Choi CU; Rha SW; Chen KY; Jin Z; Minami Y; Shin SY; Na JO; Suh SY; Lim HE; Kim JW; Kim EJ; Park CG; Seo HS; Oh DJ
    J Cardiol; 2009 Aug; 54(1):80-5. PubMed ID: 19632525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Leon MB; Kandzari DE; Eisenstein EL; Anstrom KJ; Mauri L; Cutlip DE; Nikolsky E; O'Shaughnessy C; Overlie PA; Kirtane AJ; McLaurin BT; Solomon SL; Douglas JS; Popma JJ;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1208-18. PubMed ID: 20129547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
    Waseda K; Miyazawa A; Ako J; Hasegawa T; Tsujino I; Sakurai R; Yock PG; Honda Y; Kandzari DE; Leon MB; Fitzgerald PJ;
    JACC Cardiovasc Interv; 2009 Aug; 2(8):779-84. PubMed ID: 19695548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex-specific outcomes following revascularization with zotarolimus-eluting stents: comparison of angiographic and late-term clinical results.
    Brown RA; Williams M; Barker CM; Mauri L; Meredith IT; Fajadet J; Wijns W; Leon MB; Kandzari DE
    Catheter Cardiovasc Interv; 2010 Nov; 76(6):804-13. PubMed ID: 20815043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeated sirolimus-eluting stent implantation to treat sirolimus-eluting stent and bare-metal stent restenosis.
    Nishihira K; Shibata Y; Ishikawa T; Nomura K; Nakama T; Mine D; Inoue Y; Ashikaga K; Kuriyama N; Matsuyama A; Imamura T; Asada Y; Kitamura K
    Circ J; 2010 Nov; 74(11):2329-33. PubMed ID: 20890050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcomes of sirolimus-eluting stents vs. paclitaxel-eluting stents in unprotected left main coronary artery bifurcation lesions.
    Song PS; Ryu DR; Song YB; Hahn JY; Choi JH; Choi SH; Lee SH; Hong KP; Park JE; Gwon HC
    Clin Cardiol; 2011 Jun; 34(6):378-83. PubMed ID: 21538383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-eluting stents for the treatment of ostial coronary lesions: comparison of sirolimus-eluting stent with paclitaxel-eluting stent.
    Chen J; Li JJ; Chen JL; Qiao SB; Xu B; Yang YJ; Gao RL; Qin XW; Yuan JQ; Yao M; Wu YJ; Liu HB; Dai J; You SJ
    Coron Artery Dis; 2008 Nov; 19(7):507-11. PubMed ID: 18923247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.